with Drug and Alcohol Rehabilitation Facilities · Drug and Alcohol Rehabilitation Facilities
LenderHawk analysis. Not affiliated with or endorsed by Acquisitions Anonymous.
A rehab facility with falling utilization can still show stable EBITDA margins, so buyers need to separate margin quality from bed-fill quality.
In this space, revenue per bed and occupancy matter more than headline revenue because the real operating engine is beds × utilization × daily reimbursement.
PPO and private-pay mix is critical because insurance dependence exposes the business to payer re-pricing and reimbursement friction.
A California rehab can be functionally non-buyable for a non-licensed operator if the structure requires an MSO workaround.
The buyer pool is much narrower than a normal SMB listing because many bidders will need healthcare licensing, legal comfort, and existing infrastructure.
A stock purchase may be the only practical path when contracts and billing relationships must transfer cleanly, but it also carries legacy liability risk.
The most plausible buyer is an existing operator with nearby facilities and a lead-flow advantage, not a first-time buyer.
The listing’s 2025 pro forma needs an explanation because revenue falls sharply while margins stay roughly stable and the seller still forecasts recovery.
The panel reduces the rehab business model to a simple operating equation: fill beds, keep them occupied, and maximize revenue per patient day. That metric set matters more than vague claims about brand or amenities.
When to use: Use this when underwriting inpatient or residential treatment businesses.
Heather describes the common workaround where a non-licensed owner uses a management services organization to operate around ownership restrictions. The risk is that the structure may be challenged if it is viewed as a sham rather than compliant separation.
When to use: Use this when evaluating healthcare businesses in states with ownership restrictions.
The listing asks $4.5M for a business with about $1M of EBITDA on $4M of revenue, implying roughly a 4.5x EBITDA multiple.
Bill and the panel discuss the teaser economics and whether the price is rich for the risk profile.
The facilities have about 12 beds across two locations in Los Angeles County.
The broker teaser describes the scale of the operation.
The business reportedly produced $2.3M in 2022 revenue, $4.1M in 2023, $4.7M in 2024, and a pro forma $3.7M for 2025.
Mills reads additional listing data and flags the 2025 drop.
Utilization moved from about 78% in 2022 to 64% in 2023, 58% in 2024, and 53% in the 2025 pro forma.
The hosts use this trend to question why revenue is falling while capacity expanded.
Average length of stay is roughly 21 to 22 days.
The listing includes an inpatient-style stay length that the panel uses to infer the pricing model.
Average daily revenue per patient is about $1,400 to $1,500.
The hosts use this to estimate roughly a $30,000 three-week stay.
Drug deaths per 100,000 people in the United States increased from 6.1 in 1999 to 32.6 in 2022.
Mills cites industry data to show the demand backdrop for addiction treatment.
The panel says occupancy at 53% means the business is running around six to seven patients on a 12-bed base most of the time.
They translate the utilization rate into a more intuitive operating picture.
Underwrite rehab listings from bed utilization and revenue per patient day, not just EBITDA, because occupancy can conceal weak operating fundamentals.
Why: Those metrics reveal whether the business is actually filling capacity and monetizing each stay effectively.
Demand a detailed payer mix before moving forward, because insurance-heavy revenue is more vulnerable to reimbursement changes than private pay.
Why: Heather says lenders prefer private pay and worry more when the business depends on reimbursement rates.
Have healthcare counsel review the ownership structure immediately if the business sits in a CPOM state like California.
Why: A non-licensed buyer may need an MSO structure, and the listing may not disclose that workaround clearly.
Treat a rehab acquisition as a specialist-only purchase unless you already own similar facilities nearby.
Why: The most credible buyer is likely an operator with existing licenses, staff, and referral flow.
Press hard on any unexplained year-over-year revenue drop, especially when the seller still projects a rebound.
Why: The 2025 pro forma is hard to reconcile with the earlier growth and stable margins.
Check whether the deal has to be structured as a stock sale before assuming contracts and billing relationships will transfer cleanly.
Why: Healthcare operations often depend on continuity of contracts and payer relationships.
Compare the listing against multiple similar facilities before bidding, because one deal in this space is not enough to define market pricing or margins.
Why: The panel repeatedly emphasizes that rehab economics vary widely by tier and market.
The panel sees a business that looks profitable on paper but is hard to underwrite because utilization is falling, the payer mix is opaque, and the buyer may need healthcare-specific legal workarounds. The listing becomes a case study in how healthcare compliance can matter more than advertised EBITDA.
Lesson: In regulated healthcare, legal structure and payer mix can be more important than top-line growth.
Heather mentions she invested a small amount in a rehab center in Ohio and uses that experience to explain lender conservatism toward the sector. She highlights reputational risk and payer-reimbursement issues as reasons banks are cautious.
Lesson: Lenders and investors often discount rehab deals because the risk is not just operational but also reputational and reimbursement-driven.